WRBY · Warby Parker Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active Customers | 2.71M | Q2 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $32.9M | Q2 2026 | — |
|
|
|||
| Adjusted Gross Profit non-GAAP | $136.9M | Q2 2026 | — |
| Adjusted SG&A non-GAAP | $119.3M | Q2 2026 | — |
|
|
|||
| Average Revenue per Customer | $336 | Q2 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | $6.8M | Q2 2026 | — |
| Net new stores opened | 15 | Q2 2026 | — |
|
|
|||
| Operating cash flow | $29.6M | Q2 2026 | — |
| Stores | 352 | Q2 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 12.2% | Q1 FY2026 | — |
|
|
|||
| Share Repurchase Program authorization | $100M | Full Year 2025 | — |
| Stores opened | 47 | Full Year 2025 | — |
| Total stores | 323 | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WRBY
this stock
Warby Parker Inc.
|
$3.13B | +18.9% | +13.0% | — | 14.0% |
|
ISRG
Intuitive Surgical Inc
|
$141.76B | -30.3% | +20.5% | 46.1 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.96B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$46.67B | -14.9% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.97B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WRBY | -2.1% | -1.9% | +16.7% | -2.9% | +18.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.5% | -6.3% | +2.9% | -6.8% | +5.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.